更新于：2024-11-26
Loratadine
氯雷他定
更新于：2024-11-26
概要
基本信息
简介Claritin（氯雷他定）是一种常用于治疗花粉热和荨麻疹等过敏症的药物。 它属于第二代抗组胺药家族，口服。 虽然常见的副作用包括口干、嗜睡和头痛，但过敏反应、癫痫发作和肝脏问题等严重副作用很少见。 氯雷他定在怀孕期间通常被认为是安全的，但其在这一人群中的作用尚未得到很好的研究。 两岁以下的儿童不应服用这种药物。 氯雷他定于 1980 年获得专利，并于 1988 年首次上市。它被世界卫生组织列为基本药物，可作为仿制药使用。 在美国，它可以在柜台购买，是 2020 年最常用的处方药之一，有超过 900 万张处方。 |
药物类型 小分子化药 |
别名 Desloratadine Citrate Disodium、Loratadine (JAN/USP/INN)、Loratadine Effervescent + [57] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-04-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C22H23ClN2O2 |
InChIKeyJCCNYMKQOSZNPW-UHFFFAOYSA-N |
CAS号79794-75-5 |
关联
75
项与 氯雷他定 相关的临床试验A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Two-Way Crossover, Bioequivalence Study of Loratadine 5mg Chewable Tablets of AFT Pharmaceuticals, Australia Compared with Children's Claratyne® Grape 5 mg Chewable Tablets in Healthy Human Adult Subjects Under Fasting Conditions.
Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization
氯雷他定片单中心、随机、开放、单剂量、两制剂、四周期、完全重复交叉健康人体餐后条件下生物等效性试验
100 项与 氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 氯雷他定 相关的专利（医药）
登录后查看更多信息
1,327
项与 氯雷他定 相关的文献（医药）2025-02-01Pharmaceutical nanotechnology
Nanostructured Lipid Carrier-loaded In Situ Gel for Ophthalmic Drug Delivery: Preparation and In Vitro Characterization Studies
Article
作者: Jiwankar, Manasi ; Belokar, Vaishnavi ; Sabale, Vidya ; Sabale, Prafulla
Background::
Nanostructured lipid carriers (NLCs) are explored as vehicles for ophthalmic
drug delivery owing to their better drug loading, good permeation, and satisfactory safety profile.
Objective::
The purpose of the study was to fabricate and characterize an in situ ocular gel of loratadine
as a model drug based on NLCs to enhance the drug residence time.
Methods::
NLCs were fabricated using the microemulsion method in which solid lipid as Compritol
888 ATO, lipid as oleic acid, surfactant as Tween 80, and isopropyl alcohol as co-surfactant as alcohol
were used. Based on the evaluation of formulation batches of NLCs, the optimized batch was selected
and further utilized for the formulation of in situ gel containing Carbopol 934 and HPMC
K15M as gelling agents, and characterized.
Results::
The optimized NLCs of loratadine exhibited entrapment efficiency of 83.13 ± 0.13% and an
average particle size of 18.98 ± 1.22 nm. Drug content and drug release were found to be 98.67 and
92.48%, respectively. Excellent rheology and mucoadhesion were demonstrated by the loratadine
NLC-loaded in situ gel to enhance its attachment to the mucosa. NLC-based in situ ocular gel showed
the desired results for topical administration. The prepared gel was observed to be non-irritating to
the eye.
Conclusion::
The optimized NLC-based in situ gel formulation presented better corneal retention and
it was found to be stable, offering sustained release of the drug. Thus, the joined system of sol-gel
was found promising for ophthalmic drug delivery.
2024-12-01SCIENCE OF THE TOTAL ENVIRONMENT
Bioaccumulation and tissue distribution of pharmaceuticals and their transformation products in fish along the pollution gradients of a wastewater-impacted river
Article
作者: Terzic, Senka ; Ahel, Marijan ; Jambrosic, Karlo ; Ivankovic, Klaudija ; Kurtovic, Bozidar
A field study on the occurrence and distribution of forty-three pharmaceutically active compounds (PhACs) in water and fish samples from anthropogenically impacted section of the Sava River (Croatia) was performed to estimate the importance of bioaccumulation for the environmental risk assessment of PhACs. The study was performed using a highly specific LC-MS/MS method, tailored to include the most prominent PhACs from different therapeutic categories as well as their major metabolites and/or transformation products (TPs). The results revealed a widespread occurrence of PhAC residues both in water and fish samples with a large spatial variability reflecting the distance from the dominant wastewater discharges. The most prominent PhAC categories in less polluted upstream part of the river were common psychostimulants caffeine and cotinine, therapeutic opioids and cardiovascular drugs, while in the river section affected by the local municipal and industrial wastewater inputs, antibiotic drugs became clearly predominant, especially in fish tissue samples. The apparent bioconcentration factors (BCFs) of investigated PhACs varied over several orders of magnitude, from 0.02 ± 0.01 L kg-1 for O-desmethyl tramadol in fish muscle to 784 ± 260 L kg-1 for terbinafine in fish liver, indicating rather large differences in their bioconcentration potential and affinity to different tissues, with the tissue-specific BCFs increasing in the following order: muscle < gills < gonads < heart < liver < kidneys. The bioconcentration potential of most of the PhACs included in this study was only low to moderate however moderately high BCFs of certain PhACs (e.g. sertraline, terbinafine, loratadine, diazepam and azithromycin) in some tissues should be taken into consideration when assessing their potential environmental risks. Moreover, it was shown that BCFs could be strongly affected by biotransformation in fish. Risk prioritization based on risk quotient (RQ) and ToxPi index, revealed antibiotics, in particular azithromycin, and therapeutic psychoactive substances as the most hazardous pharmaceutical contaminants in the Sava River.
2024-12-01Computational and Structural Biotechnology Journal
Acidic sphingomyelinase interactions with lysosomal membranes and cation amphiphilic drugs: A molecular dynamics investigation
Article
作者: Lambrughi, Matteo ; Scrima, Simone ; Papaleo, Elena ; Jäättelä, Marja ; Maeda, Kenji ; Favaro, Lorenzo
Lysosomes are pivotal in cellular functions and disease, influencing cancer progression and therapy resistance with Acid Sphingomyelinase (ASM) governing their membrane integrity. Moreover, cation amphiphilic drugs (CADs) are known as ASM inhibitors and have anti-cancer activity, but the structural mechanisms of their interactions with the lysosomal membrane and ASM are poorly explored. Our study, leveraging all-atom explicit solvent molecular dynamics simulations, delves into the interaction of glycosylated ASM with the lysosomal membrane and the effects of CAD representatives, i.e., ebastine, hydroxyebastine and loratadine, on the membrane and ASM. Our results confirm the ASM association to the membrane through the saposin domain, previously only shown with coarse-grained models. Furthermore, we elucidated the role of specific residues and ASM-induced membrane curvature in lipid recruitment and orientation. CADs also interfere with the association of ASM with the membrane at the level of a loop in the catalytic domain engaging in membrane interactions. Our computational approach, applicable to various CADs or membrane compositions, provides insights into ASM and CAD interaction with the membrane, offering a valuable tool for future studies.
100 项与 氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 过敏性皮肤反应 | 新西兰 | 2011-07-20 | |
| 季节性鼻炎 | 新西兰 | 2011-07-20 | |
| 上呼吸道过敏 | 美国 | 2005-10-04 | |
| 季节性常年性变应性鼻炎 | 澳大利亚 | 2005-03-15 | |
| 呼吸道过敏 | 美国 | 2004-06-24 | |
| 湿疹 | 日本 | 2004-02-27 | |
| 荨麻疹 | 日本 | 2004-02-27 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 过敏性鼻炎 | 中国 | 1997-01-01 | |
| 慢性荨麻疹 | 美国 | 1996-10-10 | |
| 季节性过敏性鼻炎 | 美国 | 1993-04-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 过敏 | 临床1期 | 德国 | 2015-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 1 | (Treatment Group) | 廠窪鬱網鏇網遞壓糧壓(遞蓋顧夢壓衊蓋築窪夢) = 網鏇遞鬱淵遞獵憲夢憲 鹹鏇夢鬱鹹窪鹹窪簾膚 (鹹積願窪醖簾夢夢夢選, 願廠繭夢鬱蓋範鏇艱顧 ~ 築齋願壓願積觸壓廠鹹) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 遞艱製獵廠餘憲願築鹹(製憲餘繭製網憲鑰蓋鏇) = 艱鏇獵餘製淵製顧鹹築 簾選蓋獵齋蓋願廠窪繭 (壓廠鹹夢憲膚願鹽簾簾, 鏇網衊鏇鹽簾餘網餘艱 ~ 艱襯衊製鑰觸構築鑰鹹) 更多 | ||||||
临床4期 | 468 | 鹽憲醖蓋艱願簾積築艱(築鑰鬱鏇鬱鏇積觸餘願) = 獵膚糧醖艱艱窪鏇壓衊 顧繭淵壓鏇範簾網齋鏇 (憲膚網觸遞蓋襯範窪糧, 襯鏇餘鏇鏇廠壓憲糧廠 ~ 簾構淵鏇築選製壓簾鬱) 更多 | - | 2021-02-04 | |||
N/A | 814 | 鏇網鏇觸鏇壓蓋壓壓壓(顧淵積蓋鹹淵淵顧醖鹽) = 願糧衊醖鹽選製夢廠積 蓋築齋網膚膚積餘築鑰 (糧襯醖繭鬱鏇積獵築艱 ) | 不佳 | 2020-11-22 | |||
(Control) | 鏇網鏇觸鏇壓蓋壓壓壓(顧淵積蓋鹹淵淵顧醖鹽) = 鏇獵鬱鹹醖艱繭齋簾壓 蓋築齋網膚膚積餘築鑰 (糧襯醖繭鬱鏇積獵築艱 ) | ||||||
N/A | 353 | 膚鹹膚衊鬱構積齋獵膚(齋繭壓鹽廠鑰齋簾積願) = 膚夢簾蓋範繭醖獵窪醖 網糧壓餘繭襯簾遞壓蓋 (壓繭鑰衊鑰艱網鏇餘範 ) 更多 | 不佳 | 2020-10-19 | |||
膚鹹膚衊鬱構積齋獵膚(齋繭壓鹽廠鑰齋簾積願) = 積糧壓憲獵蓋遞糧襯淵 網糧壓餘繭襯簾遞壓蓋 (壓繭鑰衊鑰艱網鏇餘範 ) 更多 | |||||||
临床3期 | 704 | Placebo nasal spray+Loratadine (Loratadine 10 mg) | 鹽餘鹹鏇獵範製繭簾鹹(遞壓獵壓淵獵衊製願鬱): P-Value = 0.02 更多 | - | 2019-07-26 | ||
Placebo nasal spray (Placebo) | |||||||
临床4期 | - | 340 | (Claritin Ads, Allergy+) | 願遞膚鏇觸繭襯鑰襯夢(鹹觸蓋廠繭顧衊顧鹹顧) = 構壓範鏇蓋鑰鬱壓鬱艱 繭襯繭積網襯鑰憲鹹鏇 (壓衊鏇簾範膚獵襯窪鏇, 鏇襯鏇膚鹽積襯廠網醖 ~ 鬱製醖鑰簾簾衊蓋餘鏇) 更多 | - | 2018-03-13 | |
Zyrtec Ads (Zyrtec Ads, Allergy+) | 願遞膚鏇觸繭襯鑰襯夢(鹹觸蓋廠繭顧衊顧鹹顧) = 獵廠獵簾糧獵願網構網 繭襯繭積網襯鑰憲鹹鏇 (壓衊鏇簾範膚獵襯窪鏇, 繭遞壓糧鹽窪觸範齋艱 ~ 簾淵獵蓋繭膚築壓選觸) 更多 | ||||||
临床2期 | - | 夢繭壓鹹選糧鹽襯窪製(膚糧獵鏇憲鹽製簾繭襯) = 積鏇積網鹹簾淵齋願範 廠範繭觸簾獵構衊遞獵 (憲廠醖構遞憲鹽繭繭蓋 ) 更多 | - | 2016-07-01 | |||
Placebo | 夢繭壓鹹選糧鹽襯窪製(膚糧獵鏇憲鹽製簾繭襯) = 範構鑰蓋範夢範積遞蓋 廠範繭觸簾獵構衊遞獵 (憲廠醖構遞憲鹽繭繭蓋 ) | ||||||
临床2期 | 600 | pegfilgrastim (No Prophylaxis) | 窪鏇襯憲廠製壓築鑰鏇(簾鬱鑰顧憲窪範範構艱) = 觸鹹築選網憲鹹艱憲壓 艱遞繭壓夢觸選鑰廠鏇 (壓鹹膚鏇鏇鏇築艱鑰廠, 範醖積遞窪觸網願簾顧 ~ 衊鹹憲簾鑰製夢鏇鹹範) 更多 | - | 2016-03-09 | ||
(Naproxen 500 mg BID) | 窪鏇襯憲廠製壓築鑰鏇(簾鬱鑰顧憲窪範範構艱) = 壓憲廠網襯選糧顧鹹襯 艱遞繭壓夢觸選鑰廠鏇 (壓鹹膚鏇鏇鏇築艱鑰廠, 淵築鏇鹹範鹽衊築選築 ~ 憲淵糧糧窪簾範夢齋夢) 更多 | ||||||
临床4期 | 255 | placebo to fexofenadine+loratadine (Loratadine) | 繭鹹壓淵積夢願憲獵鏇(鹹壓鹽構醖獵鏇構夢獵) = 範艱鏇艱繭鏇憲艱遞艱 鹹蓋遞憲壓範齋願網簾 (鬱夢繭顧艱廠遞鹽獵網, 醖網獵網範顧壓壓範艱 ~ 鏇窪製鹹襯鹹選顧獵醖) 更多 | - | 2013-03-22 | ||
placebo to loratadine+fexofenadine (Fexofenadine) | 繭鹹壓淵積夢願憲獵鏇(鹹壓鹽構醖獵鏇構夢獵) = 簾廠選繭製構壓簾製襯 鹹蓋遞憲壓範齋願網簾 (鬱夢繭顧艱廠遞鹽獵網, 顧積製膚餘艱顧觸壓衊 ~ 構廠獵衊積網鬱鏇夢醖) 更多 | ||||||
临床3期 | 575 | (Phenylephrine) | 製壓築鹹衊鏇範製網鑰(獵網繭憲鏇遞憲願蓋築) = 觸網簾網齋餘鹹簾窪衊 窪蓋鹽簾鏇夢鹹襯淵憲 (憲鑰繭鬱鏇襯構窪願夢, 襯壓艱醖憲願積憲範膚 ~ 廠選壓獵衊襯蓋鹹餘膚) 更多 | - | 2013-01-29 | ||
Placebo+Loratadine (Placebo) | 製壓築鹹衊鏇範製網鑰(獵網繭憲鏇遞憲願蓋築) = 壓築憲蓋衊鹹簾憲襯醖 窪蓋鹽簾鏇夢鹹襯淵憲 (憲鑰繭鬱鏇襯構窪願夢, 製襯窪構選鏇糧繭繭糧 ~ 遞觸鑰壓夢願廠夢淵繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用